Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease that develops when your blood cells are formed. It can lead to the abnormal destruction of blood cells, resulting in various symptoms.

Researchers determined patients with paroxysmal hemoglobinuria may benefit from receiving ravulizumab over the long term.

“Individuals living with rare diseases, including paroxysmal nocturnal hemoglobinuria ... “Life-threatening diseases such as PNH, aHUS and gMG, if left untreated, can lead to kidney disease ...

The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...

With biosimilars to AstraZeneca’s blockbuster rare blood disease med Soliris recently available in the U.S., nonprofit health ...

17,18,19 Fabhalta is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have hemolytic anemia. Fabhalta is only available through a ...

Empaveli (pegcetacoplan) is a prescription drug that treats paroxysmal nocturnal hemoglobinuria (PNH) by preventing the destruction of red blood cells in your blood vessels, liver, and spleen.

for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine ...